Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
PMK-Group is a venture capital organization founded by Dr. Peter M. Kovacs in 2024, headquartered in Singapore. The firm specializes in advancing healthcare solutions by investing in early-stage biotechnology and medical technology (MedTech) companies. PMK-Group is committed to guiding innovative ideas from concept to market, emphasizing long-term value creation over quick wins.
The organization employs a systematic approach to de-risking investments, addressing technical execution issues that often lead to failures in the biotech industry. PMK-Group collaborates with partners to support biotech and MedTech founders primarily from Europe and Asia, ensuring that they have the necessary resources and mentorship to succeed.
As of now, PMK-Group operates with a global outlook, focusing on sectors such as CNS/neurology, metabolic diseases, aging/longevity, diagnostics, and AI-driven health monitoring. The firm has established a reputation for achieving clinical milestones in 2-3 years, significantly faster than the industry standard.
PMK-Group primarily invests in early-stage companies within the biotech and MedTech sectors, targeting pre-seed, seed, seed+, Series A, and Series A+ stages. The organization emphasizes a systematic approach to de-risking investments, which includes addressing technical execution issues that often lead to failures in the biotech industry. Their investment strategy is designed to achieve clinical milestones in 2-3 years, significantly faster than the industry standard of 4-5 years.
The firm has a global investment outlook, with a concentration in Europe and Asia. Key focus areas include CNS/neurology, metabolic diseases, aging/longevity, diagnostics, and AI-driven health monitoring. PMK-Group seeks to partner with founders who demonstrate a strong commitment to innovation and have a clear vision for their products. The organization values long-term relationships and aims to provide not just capital, but also mentorship and access to networks that can help accelerate the growth of portfolio companies.
PMK-Group's portfolio includes 12 notable companies, each contributing to advancements in healthcare and biotechnology:
Dr. Peter M. Kovacs - Founder & CEO. Dr. Kovacs has over 20 years of experience in clinical research, biotech, and MedTech innovation. He leads PMK-Group with a vision to advance healthcare solutions through strategic investments.
Founders interested in pitching to PMK-Group should visit their contact page at https://pmk-group.com/contact. It is advisable to include a comprehensive business plan, details about the innovation, and any relevant clinical data in the pitch deck.
PMK-Group prefers warm introductions but will consider direct applications through their website. Response times may vary, but founders can expect to hear back within a few weeks if their proposal aligns with the firm's investment focus.
In March 2026, PMK-Group announced its continued investment in early-stage biotech and MedTech companies, emphasizing its commitment to achieving clinical milestones faster than the industry standard. The firm is actively expanding its portfolio, focusing on innovative solutions in healthcare.
Additionally, PMK-Group's partnership with UniPrisma has been highlighted as a key initiative to support biotech and MedTech founders from Europe and Asia, aiming to accelerate clinical validation of early innovations.
What stages does PMK-Group invest in?
PMK-Group invests in pre-seed, seed, seed+ (extension), Series A, and Series A+ (extension) stages.
What sectors does PMK-Group focus on?
The firm focuses on biotech and MedTech sectors, particularly in CNS/neurology, metabolic diseases, aging/longevity, diagnostics, and AI-driven health monitoring.
How does PMK-Group support its portfolio companies?
PMK-Group provides capital, mentorship, and access to networks, collaborating with partners to support clinical validation of early innovations.
What is the typical timeline for achieving clinical milestones?
PMK-Group aims to achieve clinical milestones in 2-3 years, significantly faster than the industry standard of 4-5 years.
How can founders pitch to PMK-Group?
Founders can pitch to PMK-Group through their contact page on the official website. It is recommended to include a clear business plan and details about the innovation.
What makes PMK-Group different from other investors?
PMK-Group differentiates itself by focusing on systematic de-risking of investments and providing extensive support for clinical development, rather than purely capital deployment.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.